New gene therapy aims to fix protein deficiency in lung and liver disease
NCT ID NCT07227207
First seen Nov 12, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tests a new treatment called TSRA-196 for people with a severe form of Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can damage the lungs and liver. The therapy is designed to help the body produce more of the protective protein it is missing. The trial will enroll about 72 adults aged 18 to 70 and will first check safety, then see if the treatment can raise protein levels to normal.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.